Related Experiment Video

Updated: Jun 24, 2025

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

9.5K

Pharmacokinetic enhancement of oncolytic virus M1 by inhibiting JAK‒STAT pathway

Jingyi Tan1, Jiayu Zhang2, Cheng Hu3

  • 1Department of Pharmacology, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou 510080, China.

Acta Pharmaceutica Sinica. B
|June 3, 2024
PubMed

Insights

This study reveals that inhibiting the JAK-STAT pathway improves oncolytic virus M1 (OVM) pharmacokinetics. This leads to better tumor targeting, enhanced accumulation, and increased effectiveness against cancer, while also boosting anti-tumor immunity.

Area of Science:

  • Oncology
  • Virology
  • Pharmacology

Background:

  • Oncolytic viruses (OVs) are replication-competent viruses that selectively destroy cancer cells.
  • Understanding OV pharmacokinetics is crucial for optimizing their therapeutic potential.
  • Mechanistic links between OV pharmacokinetics and antitumor efficacy require further elucidation.

Purpose of the Study:

  • To characterize the pharmacokinetic profile of oncolytic virus M1 (OVM) in vivo.
  • To identify key modulators of OVM pharmacokinetics.
  • To investigate the impact of modulating OVM pharmacokinetics on antitumor efficacy and immune response.

Main Methods:

  • Characterization of OVM pharmacokinetics in immunocompetent mouse tumor models.
  • Investigation of the JAK-STAT pathway's role in OVM pharmacokinetics.
  • Assessment of viral accumulation, AUC, Cmax, and antitumor efficacy following JAK-STAT pathway suppression.
  • Evaluation of T cell recruitment and activation in the tumor microenvironment.

Main Results:

  • The JAK-STAT pathway was identified as a key modulator of OVM pharmacokinetics.
  • Suppression of the JAK-STAT pathway ameliorated early OVM pharmacokinetics.
  • JAK-STAT inhibition led to enhanced tumor-specific viral accumulation, increased AUC and Cmax, and improved antitumor efficacy.
  • Improved OVM pharmacokinetics promoted T cell recruitment and activation, enhancing synergy with immune checkpoint blockade.

Conclusions:

  • This study advances the understanding of the pharmacokinetic-pharmacodynamic relationship in oncolytic virus therapy.
  • Modulating the JAK-STAT pathway represents a promising strategy to optimize OVM therapy.
  • Enhanced OVM pharmacokinetics can improve antitumor efficacy and potentiate combination therapies, such as with anti-PD-L1.
Keywords:
AnticancerJAK‒STATOncolytic virusPharmacokinetics

More Related Videos

Genome-wide RNAi Screening to Identify Host Factors That Modulate Oncolytic Virus Therapy08:51

Genome-wide RNAi Screening to Identify Host Factors That Modulate Oncolytic Virus Therapy

Published on: April 3, 2018

9.1K
Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants07:39

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

73

Related Concept Videos

The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
8.8K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
3.5K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
5.4K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.3K
cAMP-dependent Protein Kinase Pathways01:25

cAMP-dependent Protein Kinase Pathways

Cyclic Adenosine Monophosphate (cAMP) is an essential second messenger that activates protein kinase A (PKA) and regulates various biological processes. A single epinephrine molecule binds to GPCR and activates several heterotrimeric G proteins, each stimulating multiple adenylyl cyclase, amplifying the signal, and synthesizing large numbers of cAMP molecules. Small changes in cAMP concentration affect PKA activity. The binding of four cAMP molecules induces a conformational change in PKA,...
6.3K